• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients.

作者信息

Nowak Alexandra, Hemmingsson Peter, Evans Marie, Wijkström Julia

机构信息

Division of Renal Medicine, Department Clinical Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Department of Renal Medicine, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Nephrol Dial Transplant. 2023 May 31;38(6):1564-1566. doi: 10.1093/ndt/gfad010.

DOI:10.1093/ndt/gfad010
PMID:36652995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10229291/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482c/10229291/9691f764d8fa/gfad010fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482c/10229291/b0e6c7521b65/gfad010fig1g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482c/10229291/9691f764d8fa/gfad010fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482c/10229291/b0e6c7521b65/gfad010fig1g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/482c/10229291/9691f764d8fa/gfad010fig1.jpg

相似文献

1
Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients.在无应答和低应答肾移植受者中作为第五剂接种Nuvaxovid（NVX-CoV2373）疫苗后的血清学反应。
Nephrol Dial Transplant. 2023 May 31;38(6):1564-1566. doi: 10.1093/ndt/gfad010.
2
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.同源加强接种 SARS-CoV-2 重组刺突蛋白疫苗（NVX-CoV2373）的安全性和免疫原性：一项随机、安慰剂对照、2 期临床试验的二次分析。
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
3
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.NVX-CoV2373（TAK-019）疫苗在健康日本成年人中的安全性和免疫原性：一项 I/II 期随机对照试验的中期报告。
Vaccine. 2022 May 26;40(24):3380-3388. doi: 10.1016/j.vaccine.2022.04.035. Epub 2022 Apr 29.
4
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.不同剂量方案的新型冠状病毒重组刺突蛋白疫苗（NVX-CoV2373）在年轻和老年成年人中的效果：一项 2 期随机安慰剂对照试验。
PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct.
5
NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.与 BNT162b2 和 mRNA-1273 方案相比，NVX-CoV2373 诱导的针对原始 SARS-CoV-2 和 VOC 的细胞和体液免疫。
J Clin Virol. 2022 Dec;157:105321. doi: 10.1016/j.jcv.2022.105321. Epub 2022 Oct 18.
6
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.SARS-CoV-2 刺突糖蛋白疫苗候选物 NVX-CoV2373 在食蟹猴中的免疫原性和在小鼠中的保护作用。
Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.
7
Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.社论：首款基于蛋白的佐剂 Novavax 疫苗 Nuvaxovid（NVX-CoV2373）获批用于 SARS-CoV-2，有望提高疫苗接种率，并提供针对病毒变异株的免疫保护。
Med Sci Monit. 2022 Mar 1;28:e936523. doi: 10.12659/MSM.936523.
8
The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients.SARS-CoV-2 疫苗的种类会影响肾移植受者的血清学反应。
Clin Transplant. 2022 Apr;36(4):e14585. doi: 10.1111/ctr.14585. Epub 2022 Jan 18.
9
Protein vaccine NVX-CoV2373 elicits functional T cell immunity.蛋白疫苗 NVX-CoV2373 可诱导功能性 T 细胞免疫。
J Clin Invest. 2022 Oct 3;132(19):e163614. doi: 10.1172/JCI163614.
10
The Fourth Dose of CoronaVac Vaccine Results in a Small Increase of Seroconversion and Antibody Values Among Kidney Transplant Recipients.科兴新冠疫苗第四剂接种后，肾移植受者的血清转化率和抗体值略有上升。
Transplantation. 2022 Sep 1;106(9):e420-e421. doi: 10.1097/TP.0000000000004219. Epub 2022 Jun 14.

引用本文的文献

1
Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance.免疫功能低下患者COVID-19的早期联合治疗：对抗病毒持续存在和耐药性的一种有前景的方法。
BMC Infect Dis. 2025 Apr 28;25(1):616. doi: 10.1186/s12879-025-11012-3.
2
COVID-19 among kidney transplant recipients: evaluating risk factors during the initial phase of the pandemic.肾移植受者中的新型冠状病毒肺炎：评估大流行初始阶段的风险因素
Clin Kidney J. 2025 Jan 29;18(3):sfaf030. doi: 10.1093/ckj/sfaf030. eCollection 2025 Mar.

本文引用的文献

1
Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients.肾移植受者接种第三剂和第四剂异源和同源新冠疫苗后的免疫反应。
EClinicalMedicine. 2022 Nov;53:101642. doi: 10.1016/j.eclinm.2022.101642. Epub 2022 Sep 9.
2
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients.肾移植受者对三剂、四剂和五剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应
J Clin Med. 2022 May 4;11(9):2565. doi: 10.3390/jcm11092565.
3
A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
严格血清阴性肾移植受者中的第四种SARS-CoV-2 mRNA疫苗。
Kidney Int. 2022 Apr;101(4):825-826. doi: 10.1016/j.kint.2022.01.017. Epub 2022 Feb 12.
4
Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series: Erratum.实体器官移植受者对SARS-CoV-2疫苗第四剂的抗体反应：病例系列：勘误
Transplantation. 2022 Feb 1;106(2):e177. doi: 10.1097/TP.0000000000004056.
5
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
6
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.RECOVAC 免疫反应研究：COVID-19 疫苗在慢性肾脏病、透析或肾移植患者中的免疫原性、耐受性和安全性。
Transplantation. 2022 Apr 1;106(4):821-834. doi: 10.1097/TP.0000000000003983.